AR066627A1 - Medio y metodos para mejorar la diferenciacion de celulas madre hematopoyeticas - Google Patents

Medio y metodos para mejorar la diferenciacion de celulas madre hematopoyeticas

Info

Publication number
AR066627A1
AR066627A1 ARP080102109A ARP080102109A AR066627A1 AR 066627 A1 AR066627 A1 AR 066627A1 AR P080102109 A ARP080102109 A AR P080102109A AR P080102109 A ARP080102109 A AR P080102109A AR 066627 A1 AR066627 A1 AR 066627A1
Authority
AR
Argentina
Prior art keywords
cells
hematopoyetic
differentiation
methods
improve
Prior art date
Application number
ARP080102109A
Other languages
English (en)
Original Assignee
Pangenetics Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38846927&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR066627(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pangenetics Bv filed Critical Pangenetics Bv
Publication of AR066627A1 publication Critical patent/AR066627A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/52—CD40, CD40-ligand (CD154)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invencion provee medios y un método para estimular la produccion de células hematopoyéticas diferenciadas in un cultivo que comprende células progenitoras hematopoyéticas, linfocitos (preferentemente células T) y monocitos/macrofagos y/o células dendríticas. Los métodos involucran entre otros cultivar dichas células o precursores de la misma en presencia de una molécula de union específica para una molécula co-estimuladora expresada en dichos monocitos/macrofagos y/o células dendríticas o en dichos linfocitos (preferentemente células T)
ARP080102109A 2007-05-16 2008-05-16 Medio y metodos para mejorar la diferenciacion de celulas madre hematopoyeticas AR066627A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/NL2007/050228 WO2008140296A1 (en) 2007-05-16 2007-05-16 Means and methods for enhancing differentiation of haematopoietic progenitor cells

Publications (1)

Publication Number Publication Date
AR066627A1 true AR066627A1 (es) 2009-09-02

Family

ID=38846927

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080102109A AR066627A1 (es) 2007-05-16 2008-05-16 Medio y metodos para mejorar la diferenciacion de celulas madre hematopoyeticas

Country Status (9)

Country Link
US (1) US20100316632A1 (es)
JP (1) JP2010526554A (es)
KR (1) KR20100031503A (es)
AR (1) AR066627A1 (es)
BR (1) BRPI0811230A2 (es)
CA (1) CA2687266A1 (es)
CL (1) CL2008001449A1 (es)
TW (1) TW200904827A (es)
WO (2) WO2008140296A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG177651A1 (en) 2009-07-13 2012-03-29 Biogencell Ltd Method for using directing cells for specific stem/progenitor cell activation and differentiation
WO2013109104A1 (ko) * 2012-01-19 2013-07-25 서울대학교 산학협력단 인간 혈액 유래 혈구 세포괴를 포함하는 약학적 조성물
US8956870B2 (en) 2012-01-19 2015-02-17 Biogencell, Ltd. Method for using directing cells for specific stem/progenitor cell activation and differentiation
DE13746292T1 (de) * 2012-02-10 2014-10-30 Hakushinkouseikai Foundation Proliferationsmittel für monozyten, kulturmedium zur proliferation von monozyten, verfahren zur herstellung von monozyten, verfahren zur herstellung dendritischer zellen und verfahren zur herstellung eines impfstoffs mit dendritischen zellen

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002540764A (ja) * 1999-02-12 2002-12-03 ジェネティックス・インスチチュート・インコーポレーテッド Ｂ７分子と反応するヒト化免疫グロブリンおよびそれを用いた治療方法

Also Published As

Publication number Publication date
KR20100031503A (ko) 2010-03-22
CL2008001449A1 (es) 2010-08-27
CA2687266A1 (en) 2008-11-20
TW200904827A (en) 2009-02-01
WO2008140316A1 (en) 2008-11-20
US20100316632A1 (en) 2010-12-16
BRPI0811230A2 (pt) 2014-10-21
JP2010526554A (ja) 2010-08-05
WO2008140296A1 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
AU2019268194A1 (en) Cell culture system
EP2633036A4 (en) METHODS OF DIFFERENTIATION FOR THE PRODUCTION OF GLIAL CELL POPULATIONS
IL241906A0 (en) Methods for the production and uses of pluripotent cell populations and differentiated cell populations
CY1107014T1 (el) Χρηση θρεπτικου μεσου κυτταροκαλλιεργειας ελευθερου ορου για την παραγωγη il-18bp σε κυτταρα θηλαστικων
CL2008001620A1 (es) Induccion de fenotipo tolerogenico en celulas dendriticas maduras
MY159971A (en) Multipotent/pluripotent cells and methods
WO2009120762A3 (en) Human cardiovascular progenitor cells
WO2007098150A3 (en) Photobioreactor and uses therefor
EP2896690A3 (en) Use of RNA for reprogramming somatic cells
WO2008148105A8 (en) Endometrial stem cells and methods of making and using same
WO2010017216A8 (en) Mesenchymal stromal cell populations and methods of isolating and using same
EP2190976A4 (en) METHOD FOR PRODUCING PLURIPOTENTAL STEM CELL LENGTH CELLS
IL213519A0 (en) Co-culture lymphoid tissue equivalent (lte) for an artificial immune system (ais)
WO2008121894A3 (en) Endogenous expression of hla-g and/or hla-e by mesenchymal cells
CR20140587A (es) Metodo para producir iduronato-2-sulfatasa recombinante
WO2011053860A3 (en) Mesenchymal stromal cell populations and methods of using same
CY1123467T1 (el) Θεραπευτικο εμβολιο για τη θεραπεια του παιδικου διαβητη τυπου 1, εφαρμογη του κυτταροδιαχωριστη κυτταρομετριας ροης και της μεθοδου πολλαπλασιασμου των κυτταρων treg για την παραγωγη θεραπευτικου εμβολιου για τη θεραπεια του διαβητη τυπου 1
AR066627A1 (es) Medio y metodos para mejorar la diferenciacion de celulas madre hematopoyeticas
CL2012002871A1 (es) Metodo para identificar una población de celulas tr1 en reposo que comprende la deteccion de la expresion en la superficie celular de los marcadores cd4, cd25, cd127 y cd62l; poblacion aislada de celulas tr1; metodo para disminuir una poblacion de celulas tr1; kit para identificar o aislar una poblacion de celulas tr1 en reposo y/o activadas; composicion farmaceutica que comprende una poblacion de celulas tr1 en reposo y/o activadas.
EP2117592A4 (en) METHOD AND COMPOSITION FOR REMOVING SPECIFIC CELL POPULATIONS FROM BLOOD TISSUE
WO2012094255A3 (en) Decellularized liver transplantation composition and methods
MX2009008422A (es) Proceso para la preparacion de alquilpiridinas de 5-(1-alquiltio)2-sustituidas.
WO2004072262A3 (en) Cultured cd14+ antigen presenting cells
WO2006121923A3 (en) Cns cells in vitro
EP2262511A4 (en) METHODS OF INDUCING DIFFERENTIATION OF BLOOD MONOCYTES IN FUNCTIONAL DENDRITIC CELLS

Legal Events

Date Code Title Description
FA Abandonment or withdrawal